Related Experiment Video
Updated: Aug 1, 2026
Patient Derived Cell Culture and Isolation of CD133+ Putative Cancer Stem Cells from Melanoma
Published on: March 13, 2013
Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic
1Immunology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Abstract:
We have selected GD3-deficient human melanoma cell lines, in order to investigate the function of GD3 ganglioside. This was done by treating SK-MEL-28 cells with anti-GD3 antibody (R24) and rabbit complement and subsequent subcloning of the surviving cells, resulting in the derivation of two cell lines deficient in the cell surface expression of GD3. Neither cell line (designated SK-MEL-28-N1 and SK-MEL-28-N2) had detectable cell surface expression of GD3 as analyzed with monoclonal antibody R24, and no GD3 was detectable in either cell line by glycolipid isolation, thin-layer chromatography, or resorcinol-HC1 spray, but thin-layer chromatography immunostaining with monoclonal antibody R24 showed the presence of low amounts of GD3 in both N1 and N2 (1/40 of the amount in the parent cell line in N1 and 1/500 in N2). In SK-MEL-28-N1, the residual GD3 was shown by immunofluorescence assays on permeabilized cells to be present in discrete intracellular organelles, suggesting that these cells have a defect in the transport of GD3 as well as in its synthesis. Both SK-MEL-28-N1 and -N2 had an increase in detectable GM3 expression. The mutant cell lines had altered cell morphology in comparison to the parent cell line and both had slower growth rates in vitro and lower tumorgenicity in nu/nu mice. These results indicate that GD3 ganglioside plays an important role in proliferation and growth of melanoma cells.
Insights
Researchers created GD3 ganglioside-deficient melanoma cells to study GD3
Area of Science:
- Oncology
- Glycobiology
- Cell Biology
Background:
- GD3 ganglioside is a key molecule in melanoma.
- Understanding GD3's role is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the function of GD3 ganglioside in melanoma.
- To generate and characterize GD3-deficient melanoma cell lines.
Main Methods:
- Generation of GD3-deficient cell lines (SK-MEL-28-N1, SK-MEL-28-N2) using anti-GD3 antibody and complement.
- Analysis of GD3 expression via monoclonal antibody R24, glycolipid isolation, thin-layer chromatography, and immunostaining.
- Assessment of intracellular GD3 localization using immunofluorescence assays.
- Evaluation of GM3 expression, cell morphology, growth rates, and tumorgenicity in mice.
Main Results:
- GD3-deficient cell lines showed no detectable cell surface GD3, with minimal intracellular amounts.
- Increased GM3 expression and altered cell morphology were observed in mutant cell lines.
- GD3-deficient cells exhibited slower in vitro growth and reduced tumorgenicity in vivo.
Conclusions:
- GD3 ganglioside plays a significant role in melanoma cell proliferation and growth.
- Defects in GD3 synthesis or transport impact melanoma cell behavior.
- GD3 deficiency leads to reduced tumorgenicity, suggesting therapeutic potential.
